SOURCE: Aldagen


October 15, 2010 07:00 ET

Aldagen Announces Appointment of Lyle A. Hohnke, Ph.D. as Chief Executive Officer

DURHAM, NC--(Marketwire - October 15, 2010) - Aldagen, Inc. today announced that Lyle A. Hohnke, Ph.D. will become Chief Executive Officer of the company. Dr. Hohnke has over 35 years of health care industry experience and has served on Aldagen's Board of Directors since 2008. He succeeds Tom Amick.

"We appreciate the guidance Tom has given Aldagen over the years, and thank him for his many contributions that have brought the company to its current stage of development," said Richard Kent, M.D., Chairman of Aldagen. "Lyle's involvement with the company as a Board member, and his significant fundraising and operational experience make him a great addition to Aldagen's executive management team."

Dr. Hohnke most recently served as a partner at Tullis Dickerson, a healthcare-focused venture capital fund. He has specific expertise in identifying and evaluating the commercial possibilities of new technologies, and in the technology transfer process. He has demonstrated success in establishing proprietary deal flow and assessing the needs and realities of small venture-stage companies. Prior to TD, Dr. Hohnke was a general partner of an Iowa-based venture capital fund, where he led a leveraged buyout of a division of Bayer A.G., becoming chairman and chief executive officer of Diamond Animal Health. Previously, he served as vice president for research at the University of Connecticut Health Center where he managed core research facilities and supervised the patent and licensing process. He played an integral role in leading the university into the development field as president of the University of Connecticut Research and Development Corporation, and later directed a state effort to establish a venture capital fund with state and corporate funding. He has a BA from Western Michigan University and an MA/PhD from the University of Oregon, was a postdoctoral fellow at the UCLA School of Medicine and received an MBA from the Hartford Graduate Center/RPI.

About Aldagen

Aldagen is a clinical-stage biopharmaceutical company developing proprietary regenerative cell therapies. Our product candidates consist of a specific population of a patient's own stem cells, which are isolated using our proprietary technology and which we believe have the potential to promote the regeneration of multiple types of cells and tissues, including the growth of new blood vessels. Our initial focus is on developing product candidates to address cardiovascular disease. Our cardiovascular product candidates are ALD-301 for the treatment of critical limb ischemia, ALD-201 for the treatment of ischemic heart failure, and ALD-401 for the post-acute treatment of ischemic stroke.

Contact Information

  • For more information, contact:
    Ed Field
    EVP and COO
    Email Contact

    Michelle Linn
    Linnden Communications
    Email Contact